secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001161697-22-000537
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical Q3 revenue up 28.5% to $7.8M; raises FY2022 guidance to $27.5-28.0M
--------------------------------------------------------------------------------

- Net sales $7.76M (+28.5% YoY); domestic core +16.2%, international core +46.8%, novel therapies +251.9%.
- GAAP net loss $1.2M ($0.03 diluted EPS) vs $1.1M loss ($0.02) in Q3 2021; gross margin 55.7% vs 57.9%.
- Full-year 2022 revenue guidance raised to $27.5-28.0M (from $27.0-27.5M); opex guidance lowered to $26.5-27.0M.
- Cash $16.4M; management confirms year-end cash minimum of $16.0M.
- Novel therapies pipeline: four new Phase II trials, one drug progressed to Phase III.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/0001161697-22-000537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-22-000537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer